Climb Bio Inc (CLYM) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access CLYM Annual Balance Sheets →
Observing balance sheet movements over recent quarters helps explain how Climb Bio Inc adapts its asset base and funding mix.
Quarterly Report, GAAP in USD millions
ITEM
(Jun 30 2026)
(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Assets
Cash & cash equivalent44.11
Marketable Securities, Current SH139.02
Cash & Short-term Investments183.00
Derivatives, Collateral, Regulatory, Deferred0.28
Prepaid Expense And Other Assets Current3.51
Total Current Assets186.64
Equipment/Property/Plant Net0.70
Long-term investments0.00
Other Assets, Noncurrent58.68
Operating Lease Right Of Use Asset0.45
Total Assets246.29
Liabilities
Accounts Payable, Current AC1.13
Accrued Liabilities And Other Liabilities1.74
Other Liabilities, Current3.06
Total Current Liabilities5.93
Total Long-term Debt0.00
Other liabilities, Noncurrent0.81
Operating Lease Liability Current0.26
Operating Lease Liability Noncurrent0.22
Total Liabilities6.75
Stockholders' Equity
Common Stock Value0.01
Additional Paid In Capital Common Stock556.56
Retained Earnings / Accumulated Deficit-316.95
Accumulated Other Comprehensive Income-0.07
Other Equity-0.07
Common Stockholder's Equity239.55
Total Stockholder's Equity239.55
Liabilities & Stockholder's Equity246.29
4 historic quarters locked

Sign in to unlock the full Climb Bio Inc balance sheet history.

About Climb Bio Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0001193125-26-336774

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.